Increased circulating CD3+ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma

Egor V Batorov; Natalia V Pronkina; Marina A Tikhonova; Irina V Kryuchkova; Vera V Sergeevicheva; Svetlana A Sizikova; Galina Y Ushakova; Tatiana A Aristova; Dariya S Batorova; Irina V Shishkova; Andrey V Gilevich; Ekaterina Y Shevela; Alexander A Ostanin; Elena R Chernykh

doi:10.1080/10428194.2019.1581934

Increased circulating CD3⁺ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma

Leuk Lymphoma. 2019 Oct;60(10):2488-2497. doi: 10.1080/10428194.2019.1581934. Epub 2019 Mar 11.

Authors

Affiliations

¹ Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia.
² Laboratory of Clinical Immunology, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia.
³ Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia.
⁴ Intensive Care Unit, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia.

PMID: 31609150
DOI: 10.1080/10428194.2019.1581934

Abstract

Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated recovery dynamics of circulating CD3⁺, CD4⁺, CD8⁺, CD16⁺/CD56⁺, CD19⁺, CD4⁺FOXP3⁺ lymphocytes following auto-HSCT in 79 HL patients and assessed relationship between these populations and the development of early relapse. Studied populations were not statistically significant between patients with high or standard/intermediate risk of relapse. CD3⁺ T cells at the time of engraftment were increased in patients with the early relapse of HL compared to non-relapsed patients (P_U = 0.0028). Area under the curve was 0.76 (р = .0037). In logistic regression models, CD3⁺ T cell count was associated with early relapse/progression as a trend. These findings elucidate several interactions between early systemic T cell recovery and tumor progression following HDC with auto-HSCT.

Keywords: CD3+ T cells; Hodgkin lymphoma; Lymphocyte recovery; autologous hematopoietic stem cell transplantation; early relapse.

MeSH terms

Biomarkers
CD3 Complex / metabolism
Female
Flow Cytometry
Hematopoietic Stem Cell Transplantation
Hodgkin Disease / blood*
Hodgkin Disease / diagnosis*
Hodgkin Disease / therapy
Humans
Immune Reconstitution
Immunophenotyping
Lymphocyte Count*
Male
ROC Curve
Recurrence
T-Lymphocyte Subsets* / metabolism
Transplantation, Autologous
Treatment Outcome

Substances

Biomarkers
CD3 Complex